Ten years on from their approval, GlobalData reviews their market entry strategies, pricing dynamics over time, and ...

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

It is the first of a slew of cancer drugs to now funded by Pharmac following the agency's multi-million dollar budget boost.

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

September saw several notable 'firsts' in the regulatory landscape alongside the approval of four novel drugs in the U.S. Among ...

An FDA Advisory Committee on Thursday voted against broader use of immune checkpoint inhibitors Keytruda and Opdivo developed by Merck (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY) in certain ...

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

If approved, the potential restrictions would impact Merck’s Keytruda and Bristol Myers Squibb’s Opdivo, which are marketed ...

Findings from the CheckMate 067 of patients with advanced melanoma include the longest follow-up of a checkpoint inhibitor in any tumor type.

Melanoma is a type of skin cancer that starts when pigment cells in the skin grow uncontrollably, rising for the last 30 ...

After 10 years of game-changing immunotherapies like Keytruda and Opdivo, a cancer conference celebrates — and sees more work ...

While it is highly effective in treating multiple types of cancer, its extremely high price has reignited the debate over how ...